Navigation Links
Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
Date:6/4/2013

.pdf">website.  

About Merrimack Pharmaceuticals, Inc.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.

Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness of its drug candidates in new indications and its ability to translate clinical data into future clinical success. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals and other matters that could affect the availability
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
2. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
5. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
6. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
7. Ampio Pharmaceuticals Provides Clinical Updates
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
10. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  In line with CBME ... to the community with a charity program to create ... autism. CBME China team is coordinating ... and maternity manufacturers, brand owners and distributors. All donated ... July 2015. Proceeds from the sale will be used ...
(Date:5/5/2015)... , May 5, 2015   Temptime Corporation , ... health care industry, announced today that its board of ... to chief executive officer.  Mr. Van den ... since 2011. "Renaat deeply values Temptime,s mission ... job of expanding Temptime,s products and services to organizations ...
(Date:5/5/2015)... Sysmex America, Inc., a global leader ... technology, today announces a partnership with Medicus Middleware, ... Sysmex and its distributor partners to offer a ... and clinics that connect Sysmex,s XP-300 moderately complex ... systems. Physician office-based laboratories (POL) often ...
Breaking Medicine Technology:CBME China Launches Charity Program to Support Children with Autism 2Temptime President Renaat Van den Hooff Promoted to CEO 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 3
... and Company (NYSE: LLY ) announced results ... genetic mutations and disable specific signaling pathways that can ... – a JAK2 inhibitor and a Hedgehog inhibitor – ... Research (AACR) 102nd Annual Meeting in Orlando, Fla.   ...
... N.C., April 4, 2011 Cardioxyl Pharmaceuticals, Inc. ... from studies of its lead clinical candidate, CXL-1020, ... Annual Scientific Session & Expo in New Orleans, ... demonstrate CXL-1020,s ability to work independently from other ...
Cached Medicine Technology:Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 2Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 3Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 4Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 2Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 3Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 4Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 5
(Date:5/6/2015)... Launch Corporation, LLC. is pleased to announce that ... at 17 Tanguay Avenue. Owned and operated by Rick Arnold ... location in New England. , “We are extremely excited for ... founder, co-owner and CEO of Launch. “They have established great ... seeing them continue to establish that positive growth in the ...
(Date:5/6/2015)... NC (PRWEB) May 06, 2015 LINET ... Award of Charlotte in the small business category. The ... The Mayor’s International Community Award is given on an ... area that exhibit outstanding contributions to philanthropy. Since ... the Mayor have hosted the Mayor’s International Community Awards. ...
(Date:5/6/2015)... May 06, 2015 “ Radiation Island ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... the best graphic games on iOS. , Touted as one ... exceptional. It’s loved by users, which is obvious because of ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 With ProPoint: Hand ... within Final Cut Pro X . With ProPoint: ... 3D space to further more customize each preset all with ... are given up to 90 fully customizable effect presets all ... circles, curved arrows, straight arrows, underlines, and more. , ...
(Date:5/5/2015)... May 06, 2015 The ... original research “ Priority interventions to improve the ... a participatory research of the ACCORD program ” ... “Primary care actors, including clinicians, patients and family ... pain management which included knowledge gap, “work in ...
Breaking Medicine News(10 mins):Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2Health News:Top Grossing iPhone Game, Radiation Island, Was Featured on NewsWatch 2Health News:FCPX Plugin Developer Pixel Film Studios release Propoint Hand Drawn 2Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2
... could lead to new diabetes treatments, researchers say , MONDAY, ... involved in both insulin action and insulin resistance has been ... an enzyme called PI 3-kinase plays an important role in ... In tests on cells and genetically modified mice, Joslin Diabetes ...
... ... are to offer Allergan implants as part of their standard breast augmentation package. ... (PRWEB) March 29, 2010 -- ... their ongoing attempt to provide the most comprehensive service to their patients having breast ...
... at the University of Gothenburg, Sweden, has shown in a ... the treatment of lung cancer. The discovery was made when ... transgenic mice. This resulted in inhibition of cell growth, fewer ... is being published in the journal Proceedings of the ...
... March 29, 2010 Elsevier, a world leader in ... announced that its Journal of Evidence-Based Dental Practice ... a special March 2010 issue on restorative dentistry to ... in the U.S. "As the most authoritative ...
... ... of HealthcareSource®, a pioneer in talent management solutions designed for the healthcare industry. ... ... solution provider that offers employment screening and onboarding solutions designed for human resources, ...
... levels can lead to serious health problems, experts say , ... a common health problem around the world, experts say, and ... among poor black and Hispanic children, researchers report. , In ... optimal vitamin D levels, the study found. , "This is ...
Cached Medicine News:Health News:'Jekyll and Hyde' Factor May Control Insulin Function 2Health News:Rubicon Medical To Offer Allergan Implants In Breast Enlargement Surgery 2Health News:Promising strategy for treatment of lung cancer 2Health News:Elsevier's Journal of Evidence-Based Dental Practice celebrates 10th year with special issue 2Health News:TalentWise Integrates Employment Screening with Leading Applicant Tracking Solution for Healthcare Industry TalentWise becomes HealthcareSource Certified Integration Partner For Position Manager Product 2Health News:TalentWise Integrates Employment Screening with Leading Applicant Tracking Solution for Healthcare Industry TalentWise becomes HealthcareSource Certified Integration Partner For Position Manager Product 3Health News:Minority Kids Lack Enough Vitamin D 2Health News:Minority Kids Lack Enough Vitamin D 3
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... braces provide pain relief, stabilization and comfort ... patient outcomes. ,The Aspen® "Low Profile" LSO ... When firmly tightened, using the LeverLatch mechanism, ... significant degree of functional mobility and, in ...
... Gunslinger™ Shoulder Orthosis Until now, laborious custom ... of splint. Adjustability was limited and modifications ... best, difficult and cumbersome.,The GunSlinger evolved from ... a major Boston teaching hospital. This orthosis ...
Medicine Products: